Referred to the House Committee on Oversight and Government Reform.
The bill, the Fair Pharmacies for Federal Employees Act of 2025, prohibits common ownership between pharmacies and pharmacy benefit managers (PBMs) in contracts that serve Federal employee health benefit (FEHB) plans. It makes it unlawful for the Office of Personnel Management (OPM) to contract with a qualified FEHB carrier that owns or is owned/controlled by a pharmacy or a PBM.
Scope and approach: liberals view statutory separation as pro-competition and pro-consumer; conservatives prefer market-based or antitrust enforcement rather than a statutory ban.
Relative to its intended legislative type, this bill clearly states a statutory prohibition and provides extensive definitions to delineate covered actors and activities, but it lacks essential implementation, fiscal, and enforcement detail needed for effective execution within federal contracting systems.
The bill, the Fair Pharmacies for Federal Employees Act of 2025, prohibits common ownership between pharmacies and pharmacy benefit managers (PBMs) in contracts that serve Federal employee health benefit (FEHB) plans.
It makes it unlawful for the Office of Personnel Management (OPM) to contract with a qualified FEHB carrier that owns or is owned/controlled by a pharmacy or a PBM.
It also forbids OPM or a qualified carrier from contracting or subcontracting with a PBM that directly or indirectly owns or controls a pharmacy.
On content alone, the bill is a focused administrative restriction that could be sold as an anti-conflict, consumer-protection measure and therefore has a plausible path forward. Its narrow scope helps, but it directly affects a powerful industry (PBMs, insurers, pharmacies) that would likely oppose it; there are no fiscal offsets, exemptions, or phased implementation terms to ease industry transition. Those factors make enactment possible but not likely without additional compromise or inclusion in a larger legislative vehicle.
Relative to its intended legislative type, this bill clearly states a statutory prohibition and provides extensive definitions to delineate covered actors and activities, but it lacks essential implementation, fiscal, and enforcement detail needed for effective execution within federal contracting systems.
Scope and approach: liberals view statutory separation as pro-competition and pro-consumer; conservatives prefer market-based or antitrust enforcement rather than a statutory ban.
These are examples from the analysis, not a ranked list of the most-affected groups.
Scope and approach: liberals view statutory separation as pro-competition and pro-consumer; conservatives prefer market-based or antitrust enforcement rather than a statutory ban.
A mainstream progressive would likely view this bill favorably as a targeted step to reduce vertical conflicts of interest and protect independent pharmacies and beneficiaries in the federal employee system.
They would see the prohibition on common ownership as a way to curb potential PBM practices that prioritize affiliated pharmacies over patient access and competitive pricing.
They would note that it is narrowly focused on FEHB plans, so it does not address the entire market for prescription drugs.
A pragmatic moderate would view this as a narrowly targeted anti-conflict, pro-competition reform for the federal employee health program that could be reasonable but needs careful implementation.
They would appreciate the goal of preventing anti-competitive vertical integration but would worry about administrative complexity, potential cost consequences for FEHB premiums or benefits, and possible disruption to services like mail-order/specialty pharmacies.
They would look for evidence (cost-benefit analysis) and clear transition rules before supporting.
A mainstream conservative would likely oppose the bill as an unwarranted prescriptive interference in private contracting and market arrangements, particularly because it forbids certain ownership structures rather than relying on competition or case-by-case antitrust enforcement.
They would be concerned the prohibition could raise costs, reduce efficiency, and constrain legitimate vertically integrated business models that can produce savings.
They might favor targeted enforcement by antitrust authorities over a statutory blanket ban limited to federal employee plans.
Reached or meaningfully advanced
Reached or meaningfully advanced
Still ahead
Still ahead
Still ahead
On content alone, the bill is a focused administrative restriction that could be sold as an anti-conflict, consumer-protection measure and therefore has a plausible path forward. Its narrow scope helps, but it directly affects a powerful industry (PBMs, insurers, pharmacies) that would likely oppose it; there are no fiscal offsets, exemptions, or phased implementation terms to ease industry transition. Those factors make enactment possible but not likely without additional compromise or inclusion in a larger legislative vehicle.
The bill has not accumulated any surfaced votes yet.
Scope and approach: liberals view statutory separation as pro-competition and pro-consumer; conservatives prefer market-based or antitrust…
On content alone, the bill is a focused administrative restriction that could be sold as an anti-conflict, consumer-protection measure and…
Relative to its intended legislative type, this bill clearly states a statutory prohibition and provides extensive definitions to delineate covered actors and activities, but it lacks essential implementation, fiscal, a…
Go beyond the headline summary with full stakeholder mapping, legislative design analysis, passage barriers, and lens-by-lens tradeoff breakdowns.